nodes	percent_of_prediction	percent_of_DWPC	metapath
Sucralfate—Venous thrombosis—Carboplatin—testicular cancer	0.0329	0.109	CcSEcCtD
Sucralfate—FGB—embryo—testicular cancer	0.0305	0.103	CbGeAlD
Sucralfate—Fluid overload—Carboplatin—testicular cancer	0.0286	0.095	CcSEcCtD
Sucralfate—FGA—embryo—testicular cancer	0.0261	0.088	CbGeAlD
Sucralfate—FGG—female gonad—testicular cancer	0.0218	0.0734	CbGeAlD
Sucralfate—FGB—gonad—testicular cancer	0.0207	0.0698	CbGeAlD
Sucralfate—Extravasation—Carboplatin—testicular cancer	0.0204	0.0677	CcSEcCtD
Sucralfate—FGG—testis—testicular cancer	0.0193	0.0651	CbGeAlD
Sucralfate—EGF—embryo—testicular cancer	0.019	0.0643	CbGeAlD
Sucralfate—FGA—Podofilox—Etoposide—testicular cancer	0.0179	1	CbGdCrCtD
Sucralfate—FGA—gonad—testicular cancer	0.0177	0.0597	CbGeAlD
Sucralfate—FGB—female gonad—testicular cancer	0.0168	0.0567	CbGeAlD
Sucralfate—Haemolysis—Cisplatin—testicular cancer	0.0164	0.0545	CcSEcCtD
Sucralfate—Phlebitis—Carboplatin—testicular cancer	0.015	0.0498	CcSEcCtD
Sucralfate—FGB—testis—testicular cancer	0.0149	0.0503	CbGeAlD
Sucralfate—FGA—female gonad—testicular cancer	0.0144	0.0485	CbGeAlD
Sucralfate—FGG—lymph node—testicular cancer	0.014	0.0472	CbGeAlD
Sucralfate—EGF—gonad—testicular cancer	0.0129	0.0436	CbGeAlD
Sucralfate—FGA—testis—testicular cancer	0.0128	0.043	CbGeAlD
Sucralfate—EGF—female gonad—testicular cancer	0.0105	0.0354	CbGeAlD
Sucralfate—Venous thrombosis—Cisplatin—testicular cancer	0.00966	0.0321	CcSEcCtD
Sucralfate—Extravasation—Vinblastine—testicular cancer	0.0096	0.0319	CcSEcCtD
Sucralfate—EGF—testis—testicular cancer	0.00932	0.0314	CbGeAlD
Sucralfate—FGF2—female gonad—testicular cancer	0.00927	0.0313	CbGeAlD
Sucralfate—Fluid overload—Cisplatin—testicular cancer	0.00838	0.0279	CcSEcCtD
Sucralfate—FGF2—testis—testicular cancer	0.00822	0.0277	CbGeAlD
Sucralfate—Extravasation—Bleomycin—testicular cancer	0.00811	0.027	CcSEcCtD
Sucralfate—Extravasation—Dactinomycin—testicular cancer	0.00756	0.0251	CcSEcCtD
Sucralfate—Phlebitis—Vinblastine—testicular cancer	0.00706	0.0235	CcSEcCtD
Sucralfate—Extravasation—Ifosfamide—testicular cancer	0.00693	0.023	CcSEcCtD
Sucralfate—EGF—lymph node—testicular cancer	0.00675	0.0228	CbGeAlD
Sucralfate—Infection—Carboplatin—testicular cancer	0.0063	0.0209	CcSEcCtD
Sucralfate—Extravasation—Cisplatin—testicular cancer	0.00598	0.0199	CcSEcCtD
Sucralfate—Phlebitis—Bleomycin—testicular cancer	0.00596	0.0198	CcSEcCtD
Sucralfate—FGF2—lymph node—testicular cancer	0.00596	0.0201	CbGeAlD
Sucralfate—EGF—Bladder Cancer—FGFR3—testicular cancer	0.00579	0.015	CbGpPWpGaD
Sucralfate—Phlebitis—Dactinomycin—testicular cancer	0.00556	0.0185	CcSEcCtD
Sucralfate—EGF—Differentiation Pathway—KITLG—testicular cancer	0.00549	0.0143	CbGpPWpGaD
Sucralfate—Extravasation—Etoposide—testicular cancer	0.00547	0.0182	CcSEcCtD
Sucralfate—Phlebitis—Ifosfamide—testicular cancer	0.0051	0.0169	CcSEcCtD
Sucralfate—Body temperature increased—Carboplatin—testicular cancer	0.00501	0.0167	CcSEcCtD
Sucralfate—Venous thrombosis—Epirubicin—testicular cancer	0.00496	0.0165	CcSEcCtD
Sucralfate—FGF2—FGFR ligand binding and activation—FGFR3—testicular cancer	0.00465	0.0121	CbGpPWpGaD
Sucralfate—Venous thrombosis—Doxorubicin—testicular cancer	0.00459	0.0153	CcSEcCtD
Sucralfate—Phlebitis—Cisplatin—testicular cancer	0.00439	0.0146	CcSEcCtD
Sucralfate—Lung disorder—Methotrexate—testicular cancer	0.00404	0.0134	CcSEcCtD
Sucralfate—Phlebitis—Etoposide—testicular cancer	0.00402	0.0134	CcSEcCtD
Sucralfate—FGF2—SHC-mediated cascade—FGFR3—testicular cancer	0.00387	0.01	CbGpPWpGaD
Sucralfate—Hyponatraemia—Cisplatin—testicular cancer	0.0038	0.0126	CcSEcCtD
Sucralfate—Lung disorder—Epirubicin—testicular cancer	0.00378	0.0126	CcSEcCtD
Sucralfate—EGF—Differentiation Pathway—KIT—testicular cancer	0.00375	0.00974	CbGpPWpGaD
Sucralfate—Lung disorder—Doxorubicin—testicular cancer	0.0035	0.0116	CcSEcCtD
Sucralfate—FGF2—Differentiation Pathway—KITLG—testicular cancer	0.00348	0.00903	CbGpPWpGaD
Sucralfate—EGF—Constitutive PI3K/AKT Signaling in Cancer—KITLG—testicular cancer	0.00344	0.00895	CbGpPWpGaD
Sucralfate—EGF—Downstream signaling events of B Cell Receptor (BCR)—BCL10—testicular cancer	0.00336	0.00873	CbGpPWpGaD
Sucralfate—Extravasation—Methotrexate—testicular cancer	0.00328	0.0109	CcSEcCtD
Sucralfate—Infection—Chlorambucil—testicular cancer	0.00324	0.0108	CcSEcCtD
Sucralfate—ALB—testis—testicular cancer	0.00322	0.0109	CbGeAlD
Sucralfate—EGF—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	0.00321	0.00833	CbGpPWpGaD
Sucralfate—EGF—PI-3K cascade—KITLG—testicular cancer	0.0031	0.00806	CbGpPWpGaD
Sucralfate—Extravasation—Epirubicin—testicular cancer	0.00307	0.0102	CcSEcCtD
Sucralfate—EGF—PI3K/AKT activation—KITLG—testicular cancer	0.00303	0.00787	CbGpPWpGaD
Sucralfate—EGF—GAB1 signalosome—KITLG—testicular cancer	0.003	0.00781	CbGpPWpGaD
Sucralfate—FGF2—Negative regulation of FGFR signaling—FGFR3—testicular cancer	0.00299	0.00777	CbGpPWpGaD
Sucralfate—EGF—B Cell Activation—BCL10—testicular cancer	0.00297	0.00771	CbGpPWpGaD
Sucralfate—EGF—Role of LAT2/NTAL/LAB on calcium mobilization—KITLG—testicular cancer	0.00294	0.00763	CbGpPWpGaD
Sucralfate—FGF2—PI3K Cascade—STK11—testicular cancer	0.00284	0.00739	CbGpPWpGaD
Sucralfate—Extravasation—Doxorubicin—testicular cancer	0.00284	0.00944	CcSEcCtD
Sucralfate—FGF2—FRS2-mediated cascade—FGFR3—testicular cancer	0.00277	0.0072	CbGpPWpGaD
Sucralfate—FGF2—Signaling by FGFR mutants—FGFR3—testicular cancer	0.00272	0.00707	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—PRDM14—testicular cancer	0.00271	0.00703	CbGpPWpGaD
Sucralfate—EGF—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.00271	0.00703	CbGpPWpGaD
Sucralfate—Body temperature increased—Chlorambucil—testicular cancer	0.00258	0.00857	CcSEcCtD
Sucralfate—EGF—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—testicular cancer	0.00256	0.00665	CbGpPWpGaD
Sucralfate—Oedema—Bleomycin—testicular cancer	0.00252	0.00839	CcSEcCtD
Sucralfate—Infection—Bleomycin—testicular cancer	0.00251	0.00834	CcSEcCtD
Sucralfate—FGF2—IRS-mediated signalling—STK11—testicular cancer	0.00238	0.00618	CbGpPWpGaD
Sucralfate—FGF2—Differentiation Pathway—KIT—testicular cancer	0.00237	0.00616	CbGpPWpGaD
Sucralfate—Oedema—Dactinomycin—testicular cancer	0.00235	0.00783	CcSEcCtD
Sucralfate—EGF—Constitutive PI3K/AKT Signaling in Cancer—KIT—testicular cancer	0.00235	0.00611	CbGpPWpGaD
Sucralfate—Infection—Dactinomycin—testicular cancer	0.00234	0.00777	CcSEcCtD
Sucralfate—ALB—lymph node—testicular cancer	0.00233	0.00788	CbGeAlD
Sucralfate—EGF—Signaling by SCF-KIT—KITLG—testicular cancer	0.00232	0.00603	CbGpPWpGaD
Sucralfate—FGF2—IRS-related events—STK11—testicular cancer	0.00231	0.00601	CbGpPWpGaD
Sucralfate—EGF—PI-3K cascade—FGFR3—testicular cancer	0.00231	0.00599	CbGpPWpGaD
Sucralfate—FGF2—IRS-related events triggered by IGF1R—STK11—testicular cancer	0.00229	0.00596	CbGpPWpGaD
Sucralfate—FGF2—Phospholipase C-mediated cascade—FGFR3—testicular cancer	0.00228	0.00593	CbGpPWpGaD
Sucralfate—Phlebitis—Epirubicin—testicular cancer	0.00226	0.0075	CcSEcCtD
Sucralfate—EGF—PI3K/AKT activation—FGFR3—testicular cancer	0.00225	0.00585	CbGpPWpGaD
Sucralfate—EGF—GAB1 signalosome—FGFR3—testicular cancer	0.00223	0.0058	CbGpPWpGaD
Sucralfate—FGF2—IGF1R signaling cascade—STK11—testicular cancer	0.00223	0.0058	CbGpPWpGaD
Sucralfate—FGF2—Insulin receptor signalling cascade—STK11—testicular cancer	0.00223	0.0058	CbGpPWpGaD
Sucralfate—EGF—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.00222	0.00577	CbGpPWpGaD
Sucralfate—FGF2—Cardiac Progenitor Differentiation—KIT—testicular cancer	0.00219	0.00569	CbGpPWpGaD
Sucralfate—EGF—Signaling by ERBB4—KITLG—testicular cancer	0.00218	0.00568	CbGpPWpGaD
Sucralfate—EGF—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—testicular cancer	0.00218	0.00567	CbGpPWpGaD
Sucralfate—FGF2—Constitutive PI3K/AKT Signaling in Cancer—KITLG—testicular cancer	0.00218	0.00567	CbGpPWpGaD
Sucralfate—Oedema—Ifosfamide—testicular cancer	0.00216	0.00717	CcSEcCtD
Sucralfate—Infection—Ifosfamide—testicular cancer	0.00214	0.00712	CcSEcCtD
Sucralfate—FGF2—Downstream signaling events of B Cell Receptor (BCR)—BCL10—testicular cancer	0.00213	0.00552	CbGpPWpGaD
Sucralfate—EGF—PI-3K cascade—KIT—testicular cancer	0.00212	0.0055	CbGpPWpGaD
Sucralfate—Phlebitis—Doxorubicin—testicular cancer	0.00209	0.00694	CcSEcCtD
Sucralfate—EGF—Downstream signal transduction—KITLG—testicular cancer	0.00209	0.00542	CbGpPWpGaD
Sucralfate—EGF—Signaling by FGFR—KITLG—testicular cancer	0.00208	0.00539	CbGpPWpGaD
Sucralfate—EGF—PI3K/AKT activation—KIT—testicular cancer	0.00207	0.00537	CbGpPWpGaD
Sucralfate—EGF—Signaling by ERBB2—KITLG—testicular cancer	0.00207	0.00537	CbGpPWpGaD
Sucralfate—EGF—DAP12 signaling—KITLG—testicular cancer	0.00206	0.00534	CbGpPWpGaD
Sucralfate—FGF2—Endochondral Ossification—FGFR3—testicular cancer	0.00205	0.00533	CbGpPWpGaD
Sucralfate—EGF—GAB1 signalosome—KIT—testicular cancer	0.00205	0.00533	CbGpPWpGaD
Sucralfate—FGF2—Angiopoietin receptor Tie2-mediated signaling—MMP2—testicular cancer	0.00203	0.00529	CbGpPWpGaD
Sucralfate—FGF2—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	0.00203	0.00527	CbGpPWpGaD
Sucralfate—EGF—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.00203	0.00526	CbGpPWpGaD
Sucralfate—EGF—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	0.002	0.00521	CbGpPWpGaD
Sucralfate—Body temperature increased—Bleomycin—testicular cancer	0.002	0.00663	CcSEcCtD
Sucralfate—EGF—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.00197	0.00511	CbGpPWpGaD
Sucralfate—FGF2—PI-3K cascade—KITLG—testicular cancer	0.00196	0.0051	CbGpPWpGaD
Sucralfate—FGF2—PI3K Cascade—FGFR3—testicular cancer	0.00195	0.00508	CbGpPWpGaD
Sucralfate—Hyponatraemia—Epirubicin—testicular cancer	0.00195	0.00649	CcSEcCtD
Sucralfate—EGF—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.00193	0.00502	CbGpPWpGaD
Sucralfate—EGF—Signaling by FGFR in disease—KITLG—testicular cancer	0.00193	0.00502	CbGpPWpGaD
Sucralfate—EGF—DAP12 interactions—KITLG—testicular cancer	0.00193	0.00502	CbGpPWpGaD
Sucralfate—FGF2—PI3K/AKT activation—KITLG—testicular cancer	0.00192	0.00498	CbGpPWpGaD
Sucralfate—EGF—Signaling by EGFR—KITLG—testicular cancer	0.00192	0.00498	CbGpPWpGaD
Sucralfate—FGF2—GAB1 signalosome—KITLG—testicular cancer	0.0019	0.00494	CbGpPWpGaD
Sucralfate—EGF—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.0019	0.00494	CbGpPWpGaD
Sucralfate—EGF—Signaling by PDGF—KITLG—testicular cancer	0.00189	0.00491	CbGpPWpGaD
Sucralfate—FGF2—B Cell Activation—BCL10—testicular cancer	0.00188	0.00488	CbGpPWpGaD
Sucralfate—Body temperature increased—Dactinomycin—testicular cancer	0.00186	0.00619	CcSEcCtD
Sucralfate—Oedema—Cisplatin—testicular cancer	0.00186	0.00618	CcSEcCtD
Sucralfate—FGF2—Role of LAT2/NTAL/LAB on calcium mobilization—KITLG—testicular cancer	0.00186	0.00483	CbGpPWpGaD
Sucralfate—FGF2—Signaling by Insulin receptor—STK11—testicular cancer	0.00185	0.00482	CbGpPWpGaD
Sucralfate—Infection—Cisplatin—testicular cancer	0.00185	0.00614	CcSEcCtD
Sucralfate—Hyponatraemia—Doxorubicin—testicular cancer	0.00181	0.006	CcSEcCtD
Sucralfate—EGF—B Cell Activation—KITLG—testicular cancer	0.00179	0.00465	CbGpPWpGaD
Sucralfate—EGF—Signaling by SCF-KIT—FGFR3—testicular cancer	0.00172	0.00448	CbGpPWpGaD
Sucralfate—FGF2—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.00171	0.00445	CbGpPWpGaD
Sucralfate—EGF—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.00171	0.00445	CbGpPWpGaD
Sucralfate—Body temperature increased—Ifosfamide—testicular cancer	0.00171	0.00567	CcSEcCtD
Sucralfate—Infection—Etoposide—testicular cancer	0.00169	0.00563	CcSEcCtD
Sucralfate—EGF—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.00165	0.00429	CbGpPWpGaD
Sucralfate—EGF—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.00165	0.00429	CbGpPWpGaD
Sucralfate—FGF2—IRS-mediated signalling—FGFR3—testicular cancer	0.00164	0.00425	CbGpPWpGaD
Sucralfate—EGF—Signaling by ERBB4—FGFR3—testicular cancer	0.00162	0.00422	CbGpPWpGaD
Sucralfate—FGF2—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—testicular cancer	0.00162	0.00421	CbGpPWpGaD
Sucralfate—FGF2—IRS-related events—FGFR3—testicular cancer	0.00159	0.00413	CbGpPWpGaD
Sucralfate—EGF—Signaling by SCF-KIT—KIT—testicular cancer	0.00158	0.00411	CbGpPWpGaD
Sucralfate—FGF2—IRS-related events triggered by IGF1R—FGFR3—testicular cancer	0.00158	0.0041	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—INSL3—testicular cancer	0.00157	0.00408	CbGpPWpGaD
Sucralfate—EGF—Downstream signal transduction—FGFR3—testicular cancer	0.00155	0.00403	CbGpPWpGaD
Sucralfate—EGF—Signaling by FGFR—FGFR3—testicular cancer	0.00154	0.00401	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—INSL3—testicular cancer	0.00154	0.004	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—INSL3—testicular cancer	0.00154	0.004	CbGpPWpGaD
Sucralfate—FGF2—IGF1R signaling cascade—FGFR3—testicular cancer	0.00154	0.00399	CbGpPWpGaD
Sucralfate—FGF2—Insulin receptor signalling cascade—FGFR3—testicular cancer	0.00154	0.00399	CbGpPWpGaD
Sucralfate—EGF—Signaling by ERBB2—FGFR3—testicular cancer	0.00153	0.00399	CbGpPWpGaD
Sucralfate—EGF—DAP12 signaling—FGFR3—testicular cancer	0.00153	0.00397	CbGpPWpGaD
Sucralfate—EGF—Downstream signaling of activated FGFR—KIT—testicular cancer	0.00151	0.00394	CbGpPWpGaD
Sucralfate—EGF—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.00151	0.00391	CbGpPWpGaD
Sucralfate—EGF—Signaling by ERBB4—KIT—testicular cancer	0.00149	0.00387	CbGpPWpGaD
Sucralfate—FGF2—Constitutive PI3K/AKT Signaling in Cancer—KIT—testicular cancer	0.00149	0.00387	CbGpPWpGaD
Sucralfate—Body temperature increased—Cisplatin—testicular cancer	0.00147	0.00489	CcSEcCtD
Sucralfate—FGF2—Signaling by SCF-KIT—KITLG—testicular cancer	0.00147	0.00381	CbGpPWpGaD
Sucralfate—FGF2—PI-3K cascade—FGFR3—testicular cancer	0.00146	0.00379	CbGpPWpGaD
Sucralfate—EGF—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.00144	0.00373	CbGpPWpGaD
Sucralfate—EGF—Signaling by FGFR in disease—FGFR3—testicular cancer	0.00144	0.00373	CbGpPWpGaD
Sucralfate—EGF—DAP12 interactions—FGFR3—testicular cancer	0.00144	0.00373	CbGpPWpGaD
Sucralfate—FGF2—PI3K/AKT activation—FGFR3—testicular cancer	0.00142	0.0037	CbGpPWpGaD
Sucralfate—FGF2—Neural Crest Differentiation—FGFR3—testicular cancer	0.00142	0.0037	CbGpPWpGaD
Sucralfate—EGF—Signaling by EGFR—FGFR3—testicular cancer	0.00142	0.0037	CbGpPWpGaD
Sucralfate—EGF—Downstream signal transduction—KIT—testicular cancer	0.00142	0.0037	CbGpPWpGaD
Sucralfate—EGF—Signaling by FGFR—KIT—testicular cancer	0.00142	0.00368	CbGpPWpGaD
Sucralfate—FGF2—GAB1 signalosome—FGFR3—testicular cancer	0.00141	0.00367	CbGpPWpGaD
Sucralfate—EGF—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.00141	0.00367	CbGpPWpGaD
Sucralfate—EGF—Signaling by ERBB2—KIT—testicular cancer	0.00141	0.00366	CbGpPWpGaD
Sucralfate—EGF—Signaling by PDGF—FGFR3—testicular cancer	0.00141	0.00365	CbGpPWpGaD
Sucralfate—FGF2—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.0014	0.00365	CbGpPWpGaD
Sucralfate—EGF—DAP12 signaling—KIT—testicular cancer	0.0014	0.00364	CbGpPWpGaD
Sucralfate—FGB—Extracellular matrix organization—MMP2—testicular cancer	0.00139	0.00361	CbGpPWpGaD
Sucralfate—FGF2—Signaling by ERBB4—KITLG—testicular cancer	0.00138	0.00359	CbGpPWpGaD
Sucralfate—EGF—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.00138	0.00359	CbGpPWpGaD
Sucralfate—FGF2—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—testicular cancer	0.00138	0.00359	CbGpPWpGaD
Sucralfate—FGA—Extracellular matrix organization—MMP2—testicular cancer	0.00136	0.00354	CbGpPWpGaD
Sucralfate—FGG—Extracellular matrix organization—MMP2—testicular cancer	0.00136	0.00354	CbGpPWpGaD
Sucralfate—Body temperature increased—Etoposide—testicular cancer	0.00135	0.00448	CcSEcCtD
Sucralfate—ALB—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00134	0.00349	CbGpPWpGaD
Sucralfate—FGF2—PI-3K cascade—KIT—testicular cancer	0.00134	0.00348	CbGpPWpGaD
Sucralfate—EGF—B Cell Activation—FGFR3—testicular cancer	0.00133	0.00346	CbGpPWpGaD
Sucralfate—FGF2—Downstream signal transduction—KITLG—testicular cancer	0.00132	0.00343	CbGpPWpGaD
Sucralfate—EGF—Signaling by FGFR in disease—KIT—testicular cancer	0.00132	0.00343	CbGpPWpGaD
Sucralfate—EGF—DAP12 interactions—KIT—testicular cancer	0.00132	0.00343	CbGpPWpGaD
Sucralfate—EGF—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.00132	0.00343	CbGpPWpGaD
Sucralfate—EGF—Signaling by NGF—KITLG—testicular cancer	0.00132	0.00342	CbGpPWpGaD
Sucralfate—FGF2—Signaling by FGFR—KITLG—testicular cancer	0.00131	0.00341	CbGpPWpGaD
Sucralfate—FGF2—PI3K/AKT activation—KIT—testicular cancer	0.00131	0.0034	CbGpPWpGaD
Sucralfate—EGF—Signaling by EGFR—KIT—testicular cancer	0.00131	0.0034	CbGpPWpGaD
Sucralfate—FGF2—Signaling by ERBB2—KITLG—testicular cancer	0.00131	0.0034	CbGpPWpGaD
Sucralfate—FGF2—DAP12 signaling—KITLG—testicular cancer	0.0013	0.00338	CbGpPWpGaD
Sucralfate—FGF2—GAB1 signalosome—KIT—testicular cancer	0.0013	0.00337	CbGpPWpGaD
Sucralfate—EGF—Signaling by EGFR in Cancer—KIT—testicular cancer	0.0013	0.00337	CbGpPWpGaD
Sucralfate—EGF—Signaling by PDGF—KIT—testicular cancer	0.00129	0.00335	CbGpPWpGaD
Sucralfate—FGF2—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.00128	0.00333	CbGpPWpGaD
Sucralfate—FGF2—Signaling by Insulin receptor—FGFR3—testicular cancer	0.00128	0.00331	CbGpPWpGaD
Sucralfate—EGF—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.00127	0.00331	CbGpPWpGaD
Sucralfate—FGF2—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	0.00127	0.0033	CbGpPWpGaD
Sucralfate—EGF—Innate Immune System—BCL10—testicular cancer	0.00125	0.00324	CbGpPWpGaD
Sucralfate—FGF2—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.00124	0.00323	CbGpPWpGaD
Sucralfate—FGF2—DAP12 interactions—KITLG—testicular cancer	0.00122	0.00318	CbGpPWpGaD
Sucralfate—FGF2—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.00122	0.00318	CbGpPWpGaD
Sucralfate—FGF2—Signaling by FGFR in disease—KITLG—testicular cancer	0.00122	0.00318	CbGpPWpGaD
Sucralfate—EGF—B Cell Activation—KIT—testicular cancer	0.00122	0.00317	CbGpPWpGaD
Sucralfate—FGF2—Signaling by EGFR—KITLG—testicular cancer	0.00121	0.00315	CbGpPWpGaD
Sucralfate—FGF2—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.0012	0.00312	CbGpPWpGaD
Sucralfate—FGF2—Signaling by PDGF—KITLG—testicular cancer	0.0012	0.00311	CbGpPWpGaD
Sucralfate—EGF—Adaptive Immune System—BCL10—testicular cancer	0.0012	0.00311	CbGpPWpGaD
Sucralfate—EGF—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.00117	0.00304	CbGpPWpGaD
Sucralfate—FGF2—B Cell Activation—KITLG—testicular cancer	0.00113	0.00294	CbGpPWpGaD
Sucralfate—FGF2—Signaling by SCF-KIT—FGFR3—testicular cancer	0.00109	0.00283	CbGpPWpGaD
Sucralfate—FGF2—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.00108	0.00282	CbGpPWpGaD
Sucralfate—FGF2—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.00104	0.00271	CbGpPWpGaD
Sucralfate—FGF2—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	0.00104	0.00271	CbGpPWpGaD
Sucralfate—FGF2—Signaling by ERBB4—FGFR3—testicular cancer	0.00103	0.00267	CbGpPWpGaD
Sucralfate—Infection—Methotrexate—testicular cancer	0.00101	0.00337	CcSEcCtD
Sucralfate—FGF2—Signaling by SCF-KIT—KIT—testicular cancer	0.001	0.0026	CbGpPWpGaD
Sucralfate—FGF2—Downstream signal transduction—FGFR3—testicular cancer	0.000981	0.00255	CbGpPWpGaD
Sucralfate—EGF—Signaling by NGF—FGFR3—testicular cancer	0.000979	0.00254	CbGpPWpGaD
Sucralfate—FGF2—Signaling by FGFR—FGFR3—testicular cancer	0.000976	0.00254	CbGpPWpGaD
Sucralfate—FGF2—Signaling by ERBB2—FGFR3—testicular cancer	0.000971	0.00252	CbGpPWpGaD
Sucralfate—FGF2—DAP12 signaling—FGFR3—testicular cancer	0.000967	0.00251	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—INSL3—testicular cancer	0.000961	0.0025	CbGpPWpGaD
Sucralfate—FGF2—Downstream signaling of activated FGFR—KIT—testicular cancer	0.000958	0.00249	CbGpPWpGaD
Sucralfate—Oedema—Epirubicin—testicular cancer	0.000955	0.00317	CcSEcCtD
Sucralfate—FGF2—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.000953	0.00248	CbGpPWpGaD
Sucralfate—Infection—Epirubicin—testicular cancer	0.000949	0.00315	CcSEcCtD
Sucralfate—FGF2—Signaling by ERBB4—KIT—testicular cancer	0.000943	0.00245	CbGpPWpGaD
Sucralfate—FGF2—DAP12 interactions—FGFR3—testicular cancer	0.000909	0.00236	CbGpPWpGaD
Sucralfate—FGF2—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.000909	0.00236	CbGpPWpGaD
Sucralfate—FGF2—Signaling by FGFR in disease—FGFR3—testicular cancer	0.000909	0.00236	CbGpPWpGaD
Sucralfate—FGF2—Signaling by EGFR—FGFR3—testicular cancer	0.000901	0.00234	CbGpPWpGaD
Sucralfate—FGF2—Downstream signal transduction—KIT—testicular cancer	0.000901	0.00234	CbGpPWpGaD
Sucralfate—EGF—Signaling by NGF—KIT—testicular cancer	0.000899	0.00234	CbGpPWpGaD
Sucralfate—FGF2—Signaling by FGFR—KIT—testicular cancer	0.000896	0.00233	CbGpPWpGaD
Sucralfate—FGF2—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.000893	0.00232	CbGpPWpGaD
Sucralfate—FGF2—Signaling by ERBB2—KIT—testicular cancer	0.000892	0.00232	CbGpPWpGaD
Sucralfate—FGF2—Signaling by PDGF—FGFR3—testicular cancer	0.000889	0.00231	CbGpPWpGaD
Sucralfate—FGF2—DAP12 signaling—KIT—testicular cancer	0.000888	0.00231	CbGpPWpGaD
Sucralfate—Oedema—Doxorubicin—testicular cancer	0.000884	0.00294	CcSEcCtD
Sucralfate—Infection—Doxorubicin—testicular cancer	0.000878	0.00292	CcSEcCtD
Sucralfate—FGF2—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.000875	0.00227	CbGpPWpGaD
Sucralfate—FGF2—B Cell Activation—FGFR3—testicular cancer	0.000842	0.00219	CbGpPWpGaD
Sucralfate—FGF2—Signaling by FGFR in disease—KIT—testicular cancer	0.000835	0.00217	CbGpPWpGaD
Sucralfate—FGF2—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.000835	0.00217	CbGpPWpGaD
Sucralfate—FGF2—DAP12 interactions—KIT—testicular cancer	0.000835	0.00217	CbGpPWpGaD
Sucralfate—FGF2—Signaling by NGF—KITLG—testicular cancer	0.000834	0.00217	CbGpPWpGaD
Sucralfate—FGF2—Signaling by EGFR—KIT—testicular cancer	0.000827	0.00215	CbGpPWpGaD
Sucralfate—FGF2—Signaling by EGFR in Cancer—KIT—testicular cancer	0.00082	0.00213	CbGpPWpGaD
Sucralfate—FGF2—Signaling by PDGF—KIT—testicular cancer	0.000817	0.00212	CbGpPWpGaD
Sucralfate—Body temperature increased—Methotrexate—testicular cancer	0.000807	0.00268	CcSEcCtD
Sucralfate—FGF2—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.000805	0.00209	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—BCL10—testicular cancer	0.000788	0.00205	CbGpPWpGaD
Sucralfate—FGF2—B Cell Activation—KIT—testicular cancer	0.000773	0.00201	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—BCL10—testicular cancer	0.000757	0.00197	CbGpPWpGaD
Sucralfate—Body temperature increased—Epirubicin—testicular cancer	0.000755	0.00251	CcSEcCtD
Sucralfate—EGF—Innate Immune System—KITLG—testicular cancer	0.000751	0.00195	CbGpPWpGaD
Sucralfate—FGF2—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.00074	0.00192	CbGpPWpGaD
Sucralfate—EGF—Immune System—BCL10—testicular cancer	0.000726	0.00189	CbGpPWpGaD
Sucralfate—EGF—Adaptive Immune System—KITLG—testicular cancer	0.000721	0.00187	CbGpPWpGaD
Sucralfate—FGA—Disease—H2AFZ—testicular cancer	0.000704	0.00183	CbGpPWpGaD
Sucralfate—Body temperature increased—Doxorubicin—testicular cancer	0.000699	0.00232	CcSEcCtD
Sucralfate—ALB—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000683	0.00178	CbGpPWpGaD
Sucralfate—FGA—Disease—KITLG—testicular cancer	0.000647	0.00168	CbGpPWpGaD
Sucralfate—FGF2—Signaling by NGF—FGFR3—testicular cancer	0.00062	0.00161	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—INSL3—testicular cancer	0.000608	0.00158	CbGpPWpGaD
Sucralfate—FGF2—Signaling by NGF—KIT—testicular cancer	0.000569	0.00148	CbGpPWpGaD
Sucralfate—EGF—Innate Immune System—FGFR3—testicular cancer	0.000558	0.00145	CbGpPWpGaD
Sucralfate—FGF2—Extracellular matrix organization—MMP2—testicular cancer	0.000537	0.0014	CbGpPWpGaD
Sucralfate—EGF—Adaptive Immune System—FGFR3—testicular cancer	0.000536	0.00139	CbGpPWpGaD
Sucralfate—EGF—Innate Immune System—KIT—testicular cancer	0.000513	0.00133	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—H2AFZ—testicular cancer	0.000503	0.00131	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—STK11—testicular cancer	0.0005	0.0013	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—H2AFZ—testicular cancer	0.000493	0.00128	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—H2AFZ—testicular cancer	0.000493	0.00128	CbGpPWpGaD
Sucralfate—EGF—Adaptive Immune System—KIT—testicular cancer	0.000492	0.00128	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—STK11—testicular cancer	0.00049	0.00127	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—STK11—testicular cancer	0.00049	0.00127	CbGpPWpGaD
Sucralfate—FGA—Disease—FGFR3—testicular cancer	0.000481	0.00125	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—KITLG—testicular cancer	0.000475	0.00124	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—KITLG—testicular cancer	0.000463	0.0012	CbGpPWpGaD
Sucralfate—FGF2—Immune System—BCL10—testicular cancer	0.000459	0.00119	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—KITLG—testicular cancer	0.000457	0.00119	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—KITLG—testicular cancer	0.000453	0.00118	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—KITLG—testicular cancer	0.000453	0.00118	CbGpPWpGaD
Sucralfate—FGA—Disease—KIT—testicular cancer	0.000442	0.00115	CbGpPWpGaD
Sucralfate—EGF—Disease—H2AFZ—testicular cancer	0.000439	0.00114	CbGpPWpGaD
Sucralfate—EGF—Immune System—KITLG—testicular cancer	0.000438	0.00114	CbGpPWpGaD
Sucralfate—EGF—Disease—KITLG—testicular cancer	0.000404	0.00105	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—FGFR3—testicular cancer	0.000353	0.000918	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—FGFR3—testicular cancer	0.000344	0.000894	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—FGFR3—testicular cancer	0.000339	0.000882	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—FGFR3—testicular cancer	0.000337	0.000876	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—FGFR3—testicular cancer	0.000337	0.000876	CbGpPWpGaD
Sucralfate—FGF2—Developmental Biology—MMP2—testicular cancer	0.000326	0.000846	CbGpPWpGaD
Sucralfate—EGF—Immune System—FGFR3—testicular cancer	0.000325	0.000845	CbGpPWpGaD
Sucralfate—FGF2—Innate Immune System—KIT—testicular cancer	0.000324	0.000843	CbGpPWpGaD
Sucralfate—FGB—Signaling Pathways—KIT—testicular cancer	0.000316	0.00082	CbGpPWpGaD
Sucralfate—FGF2—Adaptive Immune System—KIT—testicular cancer	0.000312	0.00081	CbGpPWpGaD
Sucralfate—FGA—Signaling Pathways—KIT—testicular cancer	0.000309	0.000804	CbGpPWpGaD
Sucralfate—FGG—Signaling Pathways—KIT—testicular cancer	0.000309	0.000804	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—H2AFZ—testicular cancer	0.000308	0.000799	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—STK11—testicular cancer	0.000306	0.000795	CbGpPWpGaD
Sucralfate—EGF—Disease—FGFR3—testicular cancer	0.0003	0.00078	CbGpPWpGaD
Sucralfate—EGF—Immune System—KIT—testicular cancer	0.000299	0.000776	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—KITLG—testicular cancer	0.000283	0.000735	CbGpPWpGaD
Sucralfate—FGF2—Disease—H2AFZ—testicular cancer	0.000278	0.000722	CbGpPWpGaD
Sucralfate—FGF2—Immune System—KITLG—testicular cancer	0.000277	0.00072	CbGpPWpGaD
Sucralfate—EGF—Disease—KIT—testicular cancer	0.000276	0.000716	CbGpPWpGaD
Sucralfate—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000261	0.000678	CbGpPWpGaD
Sucralfate—FGF2—Disease—KITLG—testicular cancer	0.000256	0.000664	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—FGFR3—testicular cancer	0.00021	0.000546	CbGpPWpGaD
Sucralfate—FGF2—Immune System—FGFR3—testicular cancer	0.000206	0.000535	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—H2AFZ—testicular cancer	0.000195	0.000506	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—STK11—testicular cancer	0.000193	0.000503	CbGpPWpGaD
Sucralfate—EGF—Signaling Pathways—KIT—testicular cancer	0.000193	0.000502	CbGpPWpGaD
Sucralfate—FGF2—Disease—FGFR3—testicular cancer	0.00019	0.000494	CbGpPWpGaD
Sucralfate—FGF2—Immune System—KIT—testicular cancer	0.000189	0.000491	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—KITLG—testicular cancer	0.000179	0.000465	CbGpPWpGaD
Sucralfate—FGF2—Disease—KIT—testicular cancer	0.000174	0.000453	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—FGFR3—testicular cancer	0.000133	0.000346	CbGpPWpGaD
Sucralfate—FGF2—Signaling Pathways—KIT—testicular cancer	0.000122	0.000317	CbGpPWpGaD
Sucralfate—ALB—Metabolism—HPGDS—testicular cancer	0.000116	0.000302	CbGpPWpGaD
Sucralfate—ALB—Metabolism—STK11—testicular cancer	8.44e-05	0.000219	CbGpPWpGaD
